Omeros raises $16m for eye drug launch
This article was originally published in Scrip
Executive Summary
Biopharmaceutical company Omeros is selling nearly 4 million shares of its common stock to raise $16 million.The funds are intended to cover potential commercialization costs of its lead candidate OMS302, a combination pharmaceutical product designed for use during intraocular lens replacement surgery that it is hoping to launch next year.